Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis | Zendy

A. Benyamine | Zendy; Daniel Bertin | Zendy; Noémie Resseguier | Zendy; Xavier Heim | Zendy; Julien Bermudez | Zendy; David Launay | Zendy; Sylvain Dubucquoi | Zendy; Adrian Hij | Zendy; D. Farge | Zendy; Alain Lescoat | Zendy; I. BahonRiedinger | Zendy; Nouria Benmostefa | Zendy; Luc Mouthon | Zendy; JeanRobert Harlé | Zendy; Gilles Kaplanski | Zendy; P. Rossi | Zendy; Nathalie Bardin | Zendy; B. Granel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis

Author(s) -

A. Benyamine,

Daniel Bertin,

Noémie Resseguier,

Xavier Heim,

Julien Bermudez,

David Launay,

Sylvain Dubucquoi,

Adrian Hij,

D. Farge,

Alain Lescoat,

I. BahonRiedinger,

Nouria Benmostefa,

Luc Mouthon,

JeanRobert Harlé,

Gilles Kaplanski,

P. Rossi,

Nathalie Bardin,

B. Granel

Publication year - 2021

Publication title -

diagnostics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 19

ISSN - 2075-4418

DOI - 10.3390/diagnostics11061064

Subject(s) - iif , autoantibody , medicine , context (archaeology) , pathology , antibody , immunology , biology , paleontology

The detection of additional autoantibodies is of great concern in systemic sclerosis (SSc) when those included in the ACR/EULAR classification are negative. In this context, the interest of antifibrillarin (anti-U3RNP) autoantibodies (AFAs) in the routine evaluation of SSc remains unclear. We aimed to assess the relevance of AFAs and their clinical association in SSc patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

About

Learn

Discover

Explore